Bassetti Matteo, Righi Elda, Esposito Silvano, Petrosillo Nicola, Nicolini Laura
Clinica Malattie Infettive, Azienda Ospedaliera Universitaria San Martino, Largo R Benzi 10, 16132 Genova, Italy.
Future Microbiol. 2008 Dec;3(6):649-60. doi: 10.2217/17460913.3.6.649.
Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging pathogen in healthcare settings, where it causes infections that include bacteremia, pneumonia, meningitis, and urinary tract and wound infections. Antimicrobial resistance poses great limits for therapeutic options in infected patients, especially if the isolates are resistant to the carbapenems. Other therapeutic options include sulbactam, aminoglycosides, polymixyns and tigecycline. The discovery of new therapies coupled with the development of controlled clinical trial antibiotic testing combinations and the prevention of transmission of MDR Acinetobacter infection are essential to face this important hospital problem.
鲍曼不动杆菌在过去几十年中已成为医疗保健相关感染和医院感染暴发的主要原因。多重耐药鲍曼不动杆菌是医疗机构中迅速出现的病原体，可引起包括菌血症、肺炎、脑膜炎以及尿路感染和伤口感染在内的各种感染。抗菌药物耐药性给感染患者的治疗选择带来了极大限制，尤其是当分离株对碳青霉烯类耐药时。其他治疗选择包括舒巴坦、氨基糖苷类、多粘菌素和替加环素。发现新疗法、开发对照临床试验抗生素测试组合以及预防多重耐药不动杆菌感染的传播对于应对这一重要的医院问题至关重要。
